Kintara Therapeutics, Inc. (the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage therapeutics - VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates.
Company profile
Ticker
KTRA
Exchange
Website
CEO
Saiid Zarrabian
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Berry Only Inc., DelMar Pharmaceuticals, Inc.
SEC CIK
Corporate docs
Subsidiaries
Del Mar Pharmaceuticals (BC) Ltd. • 0959454 B.C. Ltd. • 0959456 B.C. Ltd. • Adgero Biopharmaceuticals Holdings, Inc. • Adgero Biopharmaceuticals, Inc. ...
IRS number
990360497
KTRA stock data
Latest filings (excl ownership)
425
Business combination disclosure
3 Apr 24
8-K
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
3 Apr 24
RW
Registration withdrawal request
13 Mar 24
8-K
Other Events
27 Feb 24
8-K
Other Events
26 Feb 24
8-K
Other Events
22 Feb 24
8-K
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
14 Feb 24
10-Q
2024 Q2
Quarterly report
14 Feb 24
8-K
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer
12 Feb 24
8-K
Other Events
18 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 216.00 k | 216.00 k | 216.00 k | 216.00 k | 216.00 k | 216.00 k |
Cash burn (monthly) | 439.67 k | 572.42 k | 986.67 k | 1.08 mm | 439.00 k | 567.75 k |
Cash used (since last report) | 2.99 mm | 3.89 mm | 6.71 mm | 7.37 mm | 2.99 mm | 3.86 mm |
Cash remaining | -2.77 mm | -3.68 mm | -6.49 mm | -7.16 mm | -2.77 mm | -3.65 mm |
Runway (months of cash) | -6.3 | -6.4 | -6.6 | -6.6 | -6.3 | -6.4 |
Institutional ownership, Q2 2023
5.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 1 |
Closed positions | 4 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 140.76 mm |
Total shares | 2.17 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Pilkiewicz Carolyn | 1.15 mm | $587.00 k |
Intracoastal Capital | 900.13 k | $1.15 mm |
Lind Global Fund II | 75.47 k | $0.00 |
Geode Capital Management | 14.04 k | $56.57 mm |
STT State Street | 10.72 k | $43.21 mm |
Acadian Asset Management | 6.48 k | $25.00 k |
Tower Research Capital | 4.78 k | $19.25 mm |
MS Morgan Stanley | 3.35 k | $13.48 mm |
Advisor | 981.00 | $3.97 mm |
JPM JPMorgan Chase & Co. | 559.00 | $2.25 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Aug 23 | Johnson Laura L. | Options Common Stock | Grant | Acquire A | No | No | 4.655 | 8,500 | 39.57 k | 8,500 |
30 Aug 23 | Tamara A Seymour | Options Common Stock | Grant | Acquire A | No | No | 4.655 | 8,500 | 39.57 k | 8,500 |
30 Aug 23 | Hoffman Robert | Options Common Stock | Grant | Acquire A | No | No | 4.655 | 23,142 | 107.73 k | 23,142 |
30 Aug 23 | Toth Robert Joseph JR | Options Common Stock | Grant | Acquire A | No | No | 4.655 | 8,500 | 39.57 k | 8,500 |
30 Aug 23 | Brown Dennis M | Options Common Stock | Grant | Acquire A | No | No | 4.655 | 10,175 | 47.36 k | 10,175 |
News
12 Health Care Stocks Moving In Friday's Intraday Session
19 Apr 24
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
5 Apr 24
12 Health Care Stocks Moving In Friday's Intraday Session
5 Apr 24
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
4 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
4 Apr 24
Press releases
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRA
11 Apr 24
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA
9 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, SCX, KTRA
8 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, KTRA, ABIO
5 Apr 24
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA
5 Apr 24